GlassScriptPhysician profile
Scott Wardlaw
NPI 1992152508
$6,550.03
in general payments reported to CMS, 2019-2025
24 companies · $2,176 in 2025
The $2,176 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $374 · 2023: $1,960 · 2024: $2,040 · 2025: $2,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,036 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,036.05 |
| Education | $140.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,445.59 | 2022-2025 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $1,208.03 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $375.74 | 2022-2025 | Entyvio, Eohilia |
| Pfizer INC. | $229.45 | 2023-2025 | |
| Gilead Sciences, INC. | $204.16 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $203.98 | 2022-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $122.64 | 2023-2025 | Dupixent |
| Medtronic, INC. | $115.81 | 2022-2025 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.76 | 2023-2024 | Xifaxan, Plenvu, Trulance |
| Phathom Pharmaceuticals, INC. | $78.39 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $62.64 | 2025 | Iqirvo |
| Lilly USA, LLC | $60.63 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $60.35 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $51.64 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $45.95 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $33.31 | 2022-2023 | |
| Micro-Tech Endoscopy USA, INC. | $32.22 | 2024-2025 | Riteclip, Biopsy Forceps |
| Ardelyx, INC. | $23.68 | 2025 | Ibsrela |
| Organon LLC | $20.02 | 2025 | Renflexis, Hadlima |
| Celgene Corporation | $16.87 | 2022 | |
| Genzyme Corporation | $15.83 | 2024 | |
| Novo Nordisk INC | $13.80 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $13.32 | 2023 | Linzess |
| Braintree Laboratories, INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Wardlaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.